EMD Serono, Pfizer, Broad Institute to Genomically Profile Lupus Patients | GenomeWeb

NEW YORK (GenomeWeb News) – EMD Serono announced on Tuesday a research agreement with Pfizer and the Broad Institute to genomically profile systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients.

As part of the project, being funded jointly by EMD Serono and Pfizer, the Broad will use biochemical and next-generation sequencing technologies to investigate samples from SLE and LN patients, as well as analyze immune cell subpopulations, in order to identify biomarkers to better define patient populations for future therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.